Comparative Effects of Using Black Seed and Cumin Seed on BCP of Obese Grade I
NCT ID: NCT05770791
Last Updated: 2023-03-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
55 participants
INTERVENTIONAL
2023-01-27
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Fenugreek and Cumin Powder on Overweight and Obese People
NCT05966935
Effect of Fenugreek Seed Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion
NCT07056712
Effect of Celery Seed on the Components of Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
NCT06061926
Effects of Legume Consumption on Adiponectin and Inflammatory Markers Among Adults
NCT01906086
Effect of Pomegranate Seed Powder on Markers of Metabolic Syndrome
NCT05944029
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
Group A Obese Grade I
Black Seed ( Nigella Sativa)
Intervention will be given once a day for 1 month, total 30 days Data will be collected at baseline and at the end of the intervention at 30th day
Group B
Group B Obese Grade I
Cumin Seed (Cuminum Cyminum)
Intervention will be given once a day for 1 month, total 30 days Data will be collected at baseline and at the end of the intervention at 30th day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Black Seed ( Nigella Sativa)
Intervention will be given once a day for 1 month, total 30 days Data will be collected at baseline and at the end of the intervention at 30th day
Cumin Seed (Cuminum Cyminum)
Intervention will be given once a day for 1 month, total 30 days Data will be collected at baseline and at the end of the intervention at 30th day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Having ulcers in GIT
* Subjects having hypertension, thyroid, diabetes or cardiovascular disorders
* Pregnant and lactating mothers
* Subjects who are using hormonal or anti-obesity medications
25 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sehat Medical Complex
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Waseem Javaid
Project Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Momina Mehmood
Role: PRINCIPAL_INVESTIGATOR
University of Lahore
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sehat Medical Complex, Lahore
Lahore, Punjab Province, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZaraYameen001-23
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.